Evidence map›Paper›PMID 25825561›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2015

Novel Βeta (β)-Thalassemia Mutation in Turkish Children.

Mustafa Ulasli, Serdar Oztuzcu, Sevil Kirkbes, Ali Bay, Yusuf Ziya Igci, Recep Bayraktar, Mehri Igci, Sercan Ergun, Ecir Ali Cakmak, Elif Aytekin and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mustafa UlasliDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Serdar OztuzcuDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Sevil KirkbesDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Ali BayDivision of Pediatric Hematology, Department of Pediatrics, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Yusuf Ziya IgciDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Recep BayraktarDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Mehri IgciDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Sercan ErgunDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Ecir Ali CakmakDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Elif AytekinDivision of Pediatric Hematology, Department of Pediatrics, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Ahmet ArslanDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310 Şehitkamil, Gaziantep, Turkey.
Gaziantep University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beta (β)-thalassemia is the most frequently observed hereditary blood disorder in the world. It is characterized by deficiency of hemoglobin β-globin gene and is also a profoundly heterogeneous both at the molecular and clinical level. In the case of β-thalassemia, there is reduced (β(+) type) or absent (β(o) type) synthesis of the beta chains of hemoglobin. β-Thalassemia clinically occurs in three main forms: major, intermedia and minor according to requirement of transfusion. The objective of this study was to evaluate β-thalassemia mutations in 89 patients ranging from 2 months to 16 years of age, who enrolled to Medical School Research and Training Hospital, Gaziantep University. The direct DNA sequence analysis was performed for mutation scanning of β-globin gene. 89 children with β-Thalassemia including all types were analyzed, 16 different β-thalassemia mutations were detected. We have also identified a novel mutation (HBB.c.-80delT, rs397509430) in the promoter region (-30 TATA box) of β-globin gene, and clinical data of patient having novel mutation was given. The β-Thalassemia mutations were determined as β-Thalassemia major type in 42 patients (47.19 %), β-Thalassemia intermedia in 4 (4.49 %), β-Thalassemia minor in 43, (48.31 %) patients. The most frequent mutation was IVS I-110 G>A, followed by IVS I-1 G>A, IVS I-6 T>C, IVS II-1 G>A, respectively.

Indexed as

Beta globin geneBeta-thalassemia (β-Thal)Molecular diagnosisβ-Thal mutations

Identifiers

PMID25825561
PMCPMC4375154
OpenAlexW2093703171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.